BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND EPAS1, MOP2, 2034, ENSG00000116016, PASD2, HIF2A, Q99814
91 results:

  • 1. epas1-mutated paragangliomas associated with haemoglobin disorders.
    Mancini M; Buffet A; Porte B; Amar L; Lussey-Lepoutre C; Crinière L; Baudin E; Meatchi T; Gimenez-Roqueplo AP; Favier J; Burnichon N
    Br J Haematol; 2024 Mar; 204(3):1054-1060. PubMed ID: 38195958
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Congenital Cyanotic Heart Disease and the Association with Pheochromocytomas and Paragangliomas.
    Jones RB; Cohen DL
    Curr Cardiol Rep; 2023 Nov; 25(11):1451-1460. PubMed ID: 37847359
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Somatic epas1 Variants in Pheochromocytoma and Paraganglioma in Patients With Sickle Cell Disease.
    White G; Nonaka D; Chung TT; Oakey RJ; Izatt L
    J Clin Endocrinol Metab; 2023 Nov; 108(12):3302-3310. PubMed ID: 37285480
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A Young Patient with Undiagnosed Polycythemia-Paraganglioma Syndrome: A Case Report.
    Alaklabi AM; Arabi TZ; Bin Saeedan MN; Alotaibi GS
    Am J Case Rep; 2023 May; 24():e938676. PubMed ID: 37160900
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [Clinicopathological analysis of superior mediastinal lymph node metastases in medullary thyroid carcinoma].
    He YY; Chen YT; Wang J; Chen MQ; Zhu YM; Ni S; Liu SY
    Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):82-87. PubMed ID: 36709124
    [No Abstract]    [Full Text] [Related]  

  • 6. Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumab.
    Verleye L; Castanares-Zapatero D; Devos C; De Gendt C; Silversmit G; Van Damme N; Hulstaert F; Thiry N; Neyt M
    Int J Gynecol Cancer; 2023 Apr; 33(4):543-548. PubMed ID: 36604121
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Paraganglioma with High Levels of Dopamine, Dopa Decarboxylase Suppression, Dopamine β-hydroxylase Upregulation and Intra-tumoral Melanin Accumulation: A Case Report with a Literature Review.
    Nezu M; Hirotsu Y; Amemiya K; Tateno T; Takizawa S; Inoue M; Mochizuki H; Hosaka K; Chik C; Oyama T; Omata M
    Intern Med; 2023 Jul; 62(13):1895-1905. PubMed ID: 36384901
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Somatic IDH1 Hotspot Variants in Chinese Patients With Pheochromocytomas and Paragangliomas.
    Li M; He Y; Pang Y; Zhang J; Feng Y; He Y; Xu X; Wei Y; Zhong D; Deng W; Wang L; Yan B; Jiang Y; Xu N; Cai H; Wen Y; Ning J; Liu Y; Gao X; Shan Z; Liu L; Teng X; Richter S; Jiang J
    J Clin Endocrinol Metab; 2023 Apr; 108(5):1215-1223. PubMed ID: 36355572
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.
    Celada L; Cubiella T; San-Juan-Guardado J; Gutiérrez G; Beiguela B; Rodriguez R; Poch M; Astudillo A; Grijalba A; Sánchez-Sobrino P; Tous M; Navarro E; Serrano T; Paja M; Valdés N; Chiara MD
    J Pathol; 2023 Jan; 259(1):103-114. PubMed ID: 36314599
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Novel Germline
    Provenzano A; Chetta M; De Filpo G; Cantini G; La Barbera A; Nesi G; Santi R; Martinelli S; Rapizzi E; Luconi M; Maggi M; Mannelli M; Ercolino T; Canu L
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013579
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Targeted Therapies in Pheochromocytoma and Paraganglioma.
    Wang K; Crona J; Beuschlein F; Grossman AB; Pacak K; Nölting S
    J Clin Endocrinol Metab; 2022 Nov; 107(11):2963-2972. PubMed ID: 35973976
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Epidemiology of Δ8THC-Related Carcinogenesis in USA: A Panel Regression and Causal Inferential Study.
    Reece AS; Hulse GK
    Int J Environ Res Public Health; 2022 Jun; 19(13):. PubMed ID: 35805384
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Genetic Analysis of Pheochromocytoma and Paraganglioma Complicating Cyanotic Congenital Heart Disease.
    Ogasawara T; Fujii Y; Kakiuchi N; Shiozawa Y; Sakamoto R; Ogawa Y; Ootani K; Ito E; Tanaka T; Watanabe K; Yoshida Y; Kimura N; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2545-2555. PubMed ID: 35730597
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.
    Moog S; Salgues B; Braik-Djellas Y; Viel T; Balvay D; Autret G; Robidel E; Gimenez-Roqueplo AP; Tavitian B; Lussey-Lepoutre C; Favier J
    Endocr Relat Cancer; 2022 May; 29(6):375-388. PubMed ID: 35348472
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures.
    Wang K; Schütze I; Gulde S; Bechmann N; Richter S; Helm J; Lauseker M; Maurer J; Reul A; Spoettl G; Klink B; William D; Knösel T; Friemel J; Bihl M; Weber A; Fankhauser M; Schober L; Vetter D; Broglie Däppen M; Ziegler CG; Ullrich M; Pietzsch J; Bornstein SR; Lottspeich C; Kroiss M; Fassnacht M; Wenter VUJ; Ladurner R; Hantel C; Reincke M; Eisenhofer G; Grossman AB; Pacak K; Beuschlein F; Auernhammer CJ; Pellegata NS; Nölting S
    Endocr Relat Cancer; 2022 May; 29(6):285-306. PubMed ID: 35324454
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Genetic Characteristics of Incidental Pheochromocytoma and Paraganglioma.
    Zhang J; Li M; Pang Y; Wang C; Wu J; Cheng Z; Li X; Lu Z; Liu Y; Guo J; Chen X; He Y; Guan X; Xu X; Wang Y; Liu J; Guo W; Hou Y; Liu L; Jiang J; Gao X
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e1835-e1842. PubMed ID: 35106577
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.
    Kamihara J; Hamilton KV; Pollard JA; Clinton CM; Madden JA; Lin J; Imamovic A; Wall CB; Wassner AJ; Weil BR; Heeney MM; Vargas SO; Kaelin WG; Janeway KA; Perini RF; Zojwalla NJ; Voss SD; DuBois SG
    N Engl J Med; 2021 Nov; 385(22):2059-2065. PubMed ID: 34818480
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity.
    Vit O; Patel M; Musil Z; Hartmann I; Frysak Z; Miettinen M; Pacak K; Petrak J
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770976
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma.
    Eckardt L; Prange-Barczynska M; Hodson EJ; Fielding JW; Cheng X; Lima JDCC; Kurlekar S; Douglas G; Ratcliffe PJ; Bishop T
    Endocr Relat Cancer; 2021 Oct; 28(12):757-772. PubMed ID: 34658364
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Incidence and outcomes of malignant ovarian germ cell tumors in Korea, 1999-2017.
    Park M; Lim J; Lee JA; Park HJ; Park BK; Lim MC; Park SY; Won YJ
    Gynecol Oncol; 2021 Oct; 163(1):79-84. PubMed ID: 34392955
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.